- Home
- NRIX vs PMT Comparison
NRIX vs PMT Comparison
Compare NRIX & PMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- PMT
- Stock Information
- Founded
- NRIX 2009
- PMT 2009
- Country
- NRIX United States
- PMT United States
- Employees
- NRIX N/A
- PMT N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- PMT Real Estate Investment Trusts
- Sector
- NRIX Health Care
- PMT Real Estate
- Exchange
- NRIX Nasdaq
- PMT Nasdaq
- Market Cap
- NRIX 970.1M
- PMT 1.1B
- IPO Year
- NRIX 2020
- PMT 2009
- Fundamental
- Price
- NRIX $11.64
- PMT $12.77
- Analyst Decision
- NRIX Strong Buy
- PMT Buy
- Analyst Count
- NRIX 16
- PMT 8
- Target Price
- NRIX $29.56
- PMT $14.64
- AVG Volume (30 Days)
- NRIX 978.7K
- PMT 916.4K
- Earning Date
- NRIX 07-09-2025
- PMT 07-22-2025
- Dividend Yield
- NRIX N/A
- PMT 12.50%
- EPS Growth
- NRIX N/A
- PMT N/A
- EPS
- NRIX N/A
- PMT 0.65
- Revenue
- NRIX $88,381,000.00
- PMT $614,826,000.00
- Revenue This Year
- NRIX $34.87
- PMT N/A
- Revenue Next Year
- NRIX N/A
- PMT $15.69
- P/E Ratio
- NRIX N/A
- PMT $19.72
- Revenue Growth
- NRIX 41.86
- PMT 13.07
- 52 Week Low
- NRIX $8.18
- PMT $11.77
- 52 Week High
- NRIX $29.56
- PMT $14.93
- Technical
- Relative Strength Index (RSI)
- NRIX 46.20
- PMT 51.29
- Support Level
- NRIX $11.13
- PMT $12.22
- Resistance Level
- NRIX $11.92
- PMT $12.89
- Average True Range (ATR)
- NRIX 0.77
- PMT 0.26
- MACD
- NRIX -0.15
- PMT -0.02
- Stochastic Oscillator
- NRIX 11.79
- PMT 51.82
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About PMT PennyMac Mortgage Investment Trust of Beneficial Interest
PennyMac Mortgage Investment Trust is a specialty finance company that invests primarily in residential mortgage loans and mortgage-related assets. The company's operations include activities such as the production and servicing of financial securities based on residential loans and the pooling and reselling of high-credit-quality mortgages. The company operates through three segments: correspondent production, credit-sensitive strategies, interest-rate-sensitive strategies. The Credit sensitive strategies segment generates income via investments in CRT arrangements, subordinate MBS, distressed loans, and real estate.